Trial Profile
Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Spartalizumab (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 28 Jun 2019 Status changed from recruiting to completed.
- 15 Apr 2019 Planned primary completion date changed from 3 Mar 2019 to 5 Jun 2019.
- 13 Feb 2019 Status changed from active, no longer recruiting to recruiting.